News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

China Puts the Kibosh on Genetic Testing, Surprising Even Genetic Experts—Effects on Recent Multi-million Dollar Investment by BGI of Shenzhen Uncertain

Prenatal testing, the most popular in China, is banned, affecting current projects at providers—another lesson for laboratories in how quickly things change

Genetic testing has been halted in China. This unexpected decree was announced in February. Government officials cited challenges surrounding “ethics, privacy, and the protection of human heredity resources, in a message posted on the China Food and Drug Administration’s website.

Authorities named prenatal DNA tests in particular as an area of concern in genetic testing. This may surprise pathologists and clinical laboratory professionals, who have regularly read about the substantial investments major Chinese companies have made in the field of gene sequencing. (more…)

Researchers at Stanford University and Intel Develop Silicon Microarray Chip Capable of Producing Clinical Pathology Laboratory Test Results in Minutes

Pathologists and clinical laboratory managers take note—this peptide chip microarray may have a role in point-of-care testing

At the heart of a new point-of-care technology is a prototype silicon chip that contains up to 9,000 peptides and allows real-time analysis in just minutes. Researchers say this technology can significantly reduce the time-to-answer when compared to existing clinical laboratory testing technologies.

This new prototype silicon chip is an on silico peptide microarray. It could help researchers better understand how proteins interact in the body. In turn, that will lead to improved diagnoses of numerous diseases. (more…)

New Super-Sensitive Clinical Lab Test Technology Combines ELISA and Nanotechnology for Simpler, Cheaper and Earlier Detection of Disease

Pathologists and clinical laboratory managers can expect to see new technology translated to a wide variety of diagnostic tests

Researchers claim a new diagnostic technology for detecting the HIV virus is 10 times more sensitive than traditional techniques. More remarkable is the fact that this new technology enables analyte detection at very low concentrations with the naked eye!

Pathologists and clinical laboratory managers won’t see this technology enter clinical use for some time. That is because the developers hope to deploy the accurate, fast, and very cheap HIV medical laboratory tests in Africa first. Once validated in actual clinical use, this radically innovative technology could be adapted for use in a wide variety of clinical laboratory tests.

Scientists at the London Centre for Nanotechnology at Imperial College London (ICL) developed the prototype biosensing mechanism, according to a press release published by EurekAlert!. They claim that the qualitative visual sensor technology is 10 times more sensitive than the current gold standard methods for measuring biomarkers. (more…)

Professor of Pathology Shares 2012 Nobel Prize in Chemistry

Nobel laureates’ work could lead to more effective medicines with fewer side effects

For the second time in a decade, a professor of pathology has been awarded a Nobel Prize. This time the recipient is Robert J. Lefkowitz, M.D., of Duke University Medical Center, who shares the 2012 Nobel Prize in Chemistry.

The prize committee based their decision on the potential of this laureate’s seminal discoveries, which could be used to develop more effective medicines. This work may also contribute to the development of companion diagnostic tests that could be offered by clinical laboratories. (more…)

Is Whole-genome Sequencing Reaching a Tipping Point for Clinical Pathology Laboratories?

High-Density Sequencing Chips Will Soon Be Able To Sequence Five Million SNPs

Rapid gene sequencing is catching the interest of progressive anatomic pathologists. These medical laboratory professionals are interested in using rapid gene sequencing technology to allow them to study tens and hundreds of genes on a patient specimen.

The technologies used in rapid gene sequencing are being developed and improved by a handful of biotech companies who are racing each other be first to deliver systems to the marketplace that can sequence whole human genomes at a cost of $1,000 or less. Some innovative medical laboratories are beginning to acquire these sequencing systems and explore how they might be used for clinical pathology laboratory testing. (more…)